SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Event Reported): July 30, 1997
AGOURON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
California 0-15609 33-0061928
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification Number)
10350 North Torrey Pines Road
La Jolla, California 92037
(Address of principal executive offices) Zip Code
(619) 622-3000
(Registrant's telephone number, including area code)
<PAGE>
Item 5. Other Events.
On July 30, 1997 the company's Board of Directors approved a two-for-one stock
split in the form of a special stock dividend of one share of common stock for
each share of the company's common stock outstanding. The record date for the
transaction is August 15, 1997 and the closing date will be on or about August
29, 1997.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
Dated: July 31, 1997
AGOURON PHARMACEUTICALS, INC.
By /s/ Peter Johnson
--------------------------
Peter Johnson
President and
Chief Executive Officer
